Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma

Pediatric Allergy and Immunology

Volumn 17, Issue 6, 2006, Pages 458-465

  Pohunek, Petr ^a   Kuna, Piotr ^b   Jorup, Carin ^c   De Boeck, Kris ^d  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b N Barlicki University Hospital No 1 of Medical University of Lodz   (Poland)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Asthma; Budesonide; Budesonide formoterol; Pulmicort; Symbicort

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL;

ABDOMINAL PAIN; ADOLESCENT; APPENDICITIS; ASTHMA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPHONIA; ENTERITIS; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; FRACTURE; GASTROENTERITIS; HEART PALPITATION; HOARSENESS; HUMAN; INHALER; LARYNGITIS; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE CRAMP; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; SCHOOL CHILD; SYMPTOMATOLOGY; TACHYCARDIA; THRUSH; TORTICOLLIS; TREATMENT OUTCOME; TREMOR; VOMITING;

ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FORCED EXPIRATORY VOLUME; HUMANS; HYDROCORTISONE; PEAK EXPIRATORY FLOW RATE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 33747887562     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2006.00425.x     Document Type: Conference Paper

References (31)

1. MYERS TR, CHATBURN RL. Pediatric asthma disease management. Respir Care Clin North Am 2000: 6: 57-74.
2. SHAPIRO G, BRONSKY EA, LAFORCE CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998: 132: 976-82.
3. TINKELMAN DG, BRONSKY EA, GROSS G, SCHOENWETTER WF, SPECTOR SL. Efficacy and safety of budesonide inhalation powder (Pulmicort Turbuhaler) during 52 weeks of treatment in adults and children with persistent asthma. J Asthma 2003: 40: 225-36.
4. SZEFLER SJ, LYZELL E, FITZPATRICK S, CRUZ-RIVERA M. Safety profile of budesonide inhalation suspension in the pediatric population: worldwide experience. Ann Allergy Asthma Immunol 2004: 93: 83-90.
5. WARNER JO, NASPITZ CK, for the International Pediatric Asthma Consensus Group. Third international pediatric consensus statement on the management of childhood asthma. Pediatr Pulmonol 1998: 25: 1-17.
6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention (updated 2004). National Institutes of Health [NIH] publication No. 02-3659. Bethesda, MD: NIH (Accessible at http://www.ginasthma. org).
7. 2 agonists on exacerbation rates of asthma in children. Pediatr Pulmonol 2003: 36: 391-8.
8. LANGTON HEWER S, HOBBS J, FRENCH D, LENNEY W. Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. Respir Med 1995: 89: 435-40.
9. RUSSELL G, WILLIAMS DAJ, WELLER P, PRICE JF. Salmetetrol xinafoate in children on high dose inhaled steroids. Ann Allergy Asthma Immunol 1995: 75: 423-8.
10. AKPINARLI A, TUNCER A, SARAÇLAR Y, ŞEKEREL BE, KALAYCI O. Effect of formoterol on clinical parameters and lung functions in patients with bronchial asthma: a randomized controlled trial. Arch Dis Child 1999: 81: 45-8.
11. VON BERG A, PAPAGEORGIOU SAXONI F, WILLE S, et al. Efficacy and tolerability of formoterol Turbuhaler® in children. Int J Clin Pract 2003: 57: 852-6.
12. TAL A, SIMON G, VERMEULEN JH, et al. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma. Pediatr Pulmonol 2002: 34: 342-50.
13. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987: 136: 225-44.
14. JUNIPER EF, GUYATT GH, FEENY DH, FERRIE PJ, GRITH LE, TOWNSEND M. Measuring quality of life in children with asthma. Qual Life Res 1996: 5: 35-46.
15. QUANJER PH, TAMMELING GJ, COTES JE, PEDERSEN OF, PESLIN R, YERNAULT JC. Lung volumes and forced ventilatory flows. Report working party: standardization of lung function tests. European Community for Steel and Coal. Eur Respir J 1993: 6 (Suppl. 16): 5-40.
16. JUNIPER EF, GUYATT GH, WILLAN A, GRITH LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994: 47: 81-7.
17. ZETTERSTRÖM O, BUHL R, MELLEM H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001: 18: 262-8.
18. BUHL R, CREEMERS JP, VONDRA V, MARTELLI NA, NAYA IP, EKSTROM T. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med 2003: 97: 323-30.
19. AGERTOFT L, PEDERSEN S. Importance of training for correct Turbuhaler use in preschool children. Acta Paediatr 1998: 87: 842-7.
20. GOREN A, NOVISKI N, AVITAL A, et al. Assessment of the ability of young children to use a powder inhaler device (Turbuhaler). Pediatr Pulmonol 1994: 18: 77-80.
21. PEDERSEN S, HANSEN OR, FUGLSANG G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990: 65: 308-10.
22. BHEEKIE A, SYCE JA, WEINBERG EG. Peak expiratory flow rate and symptom self-monitoring of asthma initiated from community pharmacies. J Clin Pharm Ther 2001: 26: 287-96.
23. GREENING AP, IND PW, NORTHFIELD M, SHAW G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994: 344: 219-24.
24. PAUWELS RA, LÖFDAHL C-G, POSTMA DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997: 337: 1405-11.
25. O'BYRNE PM, BARNES PJ, RODRIGUEZ-ROISIN R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001: 164: 1392-7.
26. O'BYRNE PM, BISGAARD H, GODARD PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005: 171: 129-36.
27. SCICCHITANO R, AALBERS R, UKENA D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004: 20: 1403-18.
28. RABE KF, PIZZICHINI E, STÄLLBERG B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild to moderate asthma: a randomized, double-blind trial. Chest 2005: in press.
29. PALMQVIST M, PERSSON G, LAZER L, ROSENBORG J, LARSSON P, LÖTVALL J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997: 10: 2489-99.
30. VAN DER WOUDE HJ, BOORSMA M, BERGQVIST PBF, WINTER TH, AALBERS R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004: 17: 89-95.
31. BALANAG VM, YUNUS F, YANG P-C, JORUP C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2005: Jul 8: [Epub ahead of print].